Diabetic retinopathy is one of the most common microvascular complications of diabetes, affecting nearly 50% of patients with diabetes. Diabetic retinopathy can affect almost anyone with diabetes, while an additional 5.4 million have undiagnosed dia

EGT022 is a RGD motif containing recombinant polypeptide from human derived protein ADAM-15 (6.1-kDa, 58 amino acids). It promotes healthy, stable blood vessel formation. It is a therapeutic agent of

Diabetic Retinopathy (DR) is one of the most important micro-vascular complications in diabetes a leading cause of acquired blindness among the people of occupational age. In persons with diabetes mellitus, retinal capillary occlusions develop, creating areas of swelling (ischemia) in the retina. Retinal ischemia stimulates neovascular proliferation that originates from pre-existing retinal venules at the optic disk or elsewhere in the retina posterior to the equator. Severe visual loss in proliferative diabetic retinopathy (PDR) results from vitreous hemorrhage and tractional retinal detachment.

 

Retinopathy of prematurity (ROP) occurs in premature neonates. In the premature baby, the retinaremains incompletely vascularized at the time of birth. Rather than continuing in a normal fashion, vasculgenesis in the premature neonatal retina becomes disrupted. Abnormal new proliferating vessels grow from the retina into the vitreous, resulting in hemorrhage and tractional detachment of the retina.

 

EGT022 is a RGD motif containing recombinant polypeptide from human derived protein ADAM-15 (6.1-kDa, 58 amino acids). It promotes healthy, stable blood vessel formation. It is a therapeutic agent of chronic ischemic diseases (diabetic retinopathy). A novel human origin EGT022 was expressed in yeast system and purified by means of chromatographic fractions. EGT022 is a single-chain polypeptide composed 58 amino acids including 9 cysteins (MW ~6.2-kDa). EGT022 is a suitable drug for treating early diabetic retinopathy and ROP by increasing the ability of endothelial cell to form three dimensional structures. EGT022 has no acute toxicity and no genotoxicity and do not induce new vessels by itself.

Preclinical

1. PCT/KR2007/000330(2007.1.19): “Pharmaceutical composition for treating vascular-related diseases comprising peptide”

2. PCT/KR2006/03283(2006.8.21): “Pharmaceutical composition for treating vascular-related diseases comprising peptide”

3. PCT/KR2006/000751(2004.3.31): “Polypeptide inducing the secretion of angiopoietin”

4. Korea 10-2006-005975(2006.1.19): “Peptide comprising RGD sequence of inducing the secretion of angoipoietin-1”

5. Korea 10-2003-0050397(2003.7.23): “Therapeutic containing human integrin binding protein or peptide for treating ophthalmopathy”

 

  - Overseas Licensing Opportunity

  - Seeking potential corporate partners